Cited 11 times in
(18)F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after Mastectomy.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 금기창 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 김용배 | - |
dc.contributor.author | 서창옥 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 이정심 | - |
dc.contributor.author | 장지석 | - |
dc.date.accessioned | 2017-02-24T11:24:56Z | - |
dc.date.available | 2017-02-24T11:24:56Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146761 | - |
dc.description.abstract | PURPOSE: The purpose of this study is to assess the utility of positron emission tomography (PET) for predicting recurrence among patients with T1-T2/N1 breast cancer who were treated with mastectomy. MATERIALS AND METHODS: Of 712 consecutive patients with T1-T2/N1 breast cancer treated during 2003-2012, 109 had undergone preoperative (18)F-fluorodeoxyglucose/PET and were included. Metabolic (maximum standardized uptake value [SUVmax]), volumetric (metabolic tumor volume [MTV]), and combined (total lesion glycolysis [TLG]) indices were measured. The resulting values were analyzed and compared with clinical outcome. RESULTS: At the median follow-up of 46.7 months, the 3-year relapse-free survival (RFS) rate was 95.2%. SUVmax (area under curve, 0.824) was more useful than MTV or TLG as a means of identifying patients at high risk for any recurrence. In multivariate analysis, SUVmax remained an independent risk factor for RFS (p=0.006). Using the method of Contal and O'Quigley, a SUVmax threshold of 5.36 showed the best predictive performance. The PET-based high-risk group (≥ 5.36 in either breast or nodes) had more T1c-T2, high-grade, hormone-receptor negative, and invasive ductal carcinoma tumors than the low-risk group (< 5.36 in both breast and nodes). The prognosis was much worse when high SUVmax (≥ 5.36) was detected in nodes (p < 0.001). In the no-radiotherapy cohort, the PET-based high-risk group had increased risk of locoregional recurrence when compared to the low-risk group (p=0.037). CONCLUSION: High SUVmax on preoperative PET showed association with elevated risk of locoregional recurrence and any recurrence. Pre-treatment PET may improve assessments of recurrence risk and clarify indications for post-mastectomy radiotherapy in this subset of patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 508~517 | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Breast Neoplasms/diagnostic imaging* | - |
dc.subject.MESH | Breast Neoplasms/pathology* | - |
dc.subject.MESH | Breast Neoplasms/radiotherapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymph Nodes/pathology | - |
dc.subject.MESH | Lymphatic Metastasis/diagnostic imaging* | - |
dc.subject.MESH | Lymphatic Metastasis/pathology* | - |
dc.subject.MESH | Lymphatic Metastasis/radiotherapy | - |
dc.subject.MESH | Mastectomy* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/prevention & control | - |
dc.subject.MESH | Positron-Emission Tomography* | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Tumor Burden | - |
dc.title | (18)F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after Mastectomy. | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Radiation Oncology | - |
dc.contributor.googleauthor | Jee Suk Chang | - |
dc.contributor.googleauthor | Jeongshim Lee | - |
dc.contributor.googleauthor | Hyun Jung Kim | - |
dc.contributor.googleauthor | Kyung Hwan Kim | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Ki Chang Keum | - |
dc.contributor.googleauthor | Chang-Ok Suh | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.identifier.doi | 10.4143/crt.2015.172 | - |
dc.contributor.localId | A00272 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A00744 | - |
dc.contributor.localId | A01919 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A03112 | - |
dc.contributor.localId | A04658 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.relation.journalsince | 2001~ | - |
dc.identifier.pmid | 26511818 | - |
dc.relation.journalbefore | ~2001 Journal of the Korean Cancer Research Association (대한암학회지) | - |
dc.subject.keyword | Breast neoplasms | - |
dc.subject.keyword | Mastectomy | - |
dc.subject.keyword | Positron-emission tomography | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Recurrence | - |
dc.contributor.alternativeName | Keum, Ki Chang | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.alternativeName | Suh, Chang Ok | - |
dc.contributor.alternativeName | Yun, Mi Jin | - |
dc.contributor.alternativeName | Lee, Jeong Shim | - |
dc.contributor.alternativeName | Chang, Jee Suk Paul | - |
dc.contributor.affiliatedAuthor | Keum, Ki Chang | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | Suh, Chang Ok | - |
dc.contributor.affiliatedAuthor | Yun, Mi Jin | - |
dc.contributor.affiliatedAuthor | Lee, Jeong Shim | - |
dc.contributor.affiliatedAuthor | Chang, Jee Suk Paul | - |
dc.citation.volume | 48 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 508 | - |
dc.citation.endPage | 517 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.48(2) : 508-517, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 47504 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.